Loading clinical trials...
Loading clinical trials...
Importance: EGFR tyrosine kinase inhibitors (EGFR-TKIs) and PD-1/PD-L1 immune checkpoint inhibitors are widely used in the treatment of non-small cell lung cancer (NSCLC). However, the safety profile...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NCT06476808 · High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), and more
NCT07361497 · Non-small Cell Lung Cancer (NSCLC)
NCT07510724 · Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), and more
NCT06305754 · Non-small Cell Lung Cancer (NSCLC)
NCT06726720 · Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions